Isodiol International Inc

OTCQB - U.S. Registered | Jun 6, 2020, 7:35 AM EDT

ISOLF:US $ 0.0715
0.006 (9.1603%)
Day Low: 0.062
Day High: 0.08
Isodiol International Inc. Upgrades to OTCQB

VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Isodiol’s common shares have been approved for trading on the OTCQB Venture Market in the United States. The trading symbol will remain as ISOLF.

The OTCQB is the ideal exchange for emerging companies.  To be eligible for the OTCQB, companies must be up to date in reporting with the U.S. Securities Exchange Commission, meet a minimum price bid test, and undergo an annual verification and management certification process.  These standards and regulations will provide investors with confidence and enhance their trading experiences.  

 “We are very pleased with this OTCQB listing.  Listing on the OTCQB is part of Isodiol’s overall strategy to increase awareness to international investors,” said Marcos Agramont, CEO of Isodiol.  “This listing will provide the Company with a significant trading platform for international shareholders and future investors, while making the Company itself easily available to American investors.”

For more information on Isodiol, please visit 

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook:
Twitter: @isodiol

Marcos Agramont, CEO & Director


Carrie Booze
North 6th Agency
212-334-9753 ext.142

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Primary Logo

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.